Search Results - Jonathan Foot

  • Showing 1 - 4 results of 4
Refine Results
  1. 1

    Targeting vascular adhesion protein-1 and myeloperoxidase with a dual inhibitor SNT-8370 in preclinical models of inflammatory disease by Elias Glaros, Jonathan Foot, Ben Rayner, Heidi Schilter, Yunjia Zhang, Martina Paumann-Page, Mauro M. Teixeira, Wolfgang Jarolimek, Shane R. Thomas

    Published in Nature Communications (2025-04-01)
    Get full text
    Article


  2. 2

    A Novel MAO-B/SSAO Inhibitor Improves Multiple Aspects of Dystrophic Phenotype in <i>mdx</i> Mice by Francesca Gasparella, Leonardo Nogara, Elena Germinario, Lucia Tibaudo, Stefano Ciciliot, Giorgia Piccoli, Francisca Carolina Venegas, Francesca Fontana, Gabriele Sales, Daniele Sabbatini, Jonathan Foot, Wolfgang Jarolimek, Bert Blaauw, Marcella Canton, Libero Vitiello

    Published in Antioxidants (2024-05-01)
    Get full text
    Article


  3. 3

    The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement by Lara Perryman, Alison Findlay, Jana Baskar, Brett Charlton, Jonathan Foot, Ross Hamilton, Dieter Hamprecht, Amar Joshi, Jessica Stolp, Craig Turner, Amna Zahoor, Wenbin Zhou, Begoña López, Susana Ravassa, Arantxa González, Wolfgang Jarolimek

    Published in Scientific Reports (2025-07-01)
    Get full text
    Article


  4. 4

    An activity‐based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti‐fibrotic therapeutic strategies by Alison Findlay, Craig Turner, Heidi Schilter, Mandar Deodhar, Wenbin Zhou, Lara Perryman, Jonathan Foot, Amna Zahoor, Yimin Yao, Ross Hamilton, Mary Brock, Christina Raso, Jessica Stolp, Marie Galati, Dieter Hamprecht, Brett Charlton, Wolfgang Jarolimek

    Published in Clinical and Translational Medicine (2021-11-01)
    Get full text
    Article


Search Tools: